RecombinantRabMAb

Recombinant Anti-PADI3 / PAD3 antibody [EPR12165(B)] (ab172959)

Submit a review Submit a question References (3)
Western blot - Anti-PADI3 / PAD3 antibody [EPR12165(B)] (ab172959)
  • Immunoprecipitation - Anti-PADI3 / PAD3 antibody [EPR12165(B)] (ab172959)
  • Anti-PADI3 / PAD3 antibody [EPR12165(B)] (ab172959)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR12165(B)] to PADI3 / PAD3
  • Suitable for: WB, IP
  • Reacts with: Human

Overview

  • Product name

    Anti-PADI3 / PAD3 antibody [EPR12165(B)]
    See all PADI3 / PAD3 primary antibodies

  • Description

    Rabbit monoclonal [EPR12165(B)] to PADI3 / PAD3

  • Host species

    Rabbit

  • Tested Applications & Species

    Application Species
    IP
    Human
    WB
    Human
    See all applications and species data

  • Immunogen

    Synthetic peptide within Human PADI3/ PAD3 aa 350-450 (Cysteine residue). The exact sequence is proprietary.
    Database link: Q9ULW8

  • Positive control

    • Human fetal muscle, skeletal muscle and skin lysates.

  • General notes

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

Applications

The Abpromise guarantee

Our Abpromise guarantee covers the use of ab172959 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Guaranteed

Tested applications are guaranteed to work and covered by our Abpromise guarantee.

Predicted

Predicted to work for this combination of applications and species but not guaranteed.

Incompatible

Does not work for this combination of applications and species.

Application Species
ICC
Human
IHC-P
Human
IP
Human
WB
Human
Application Abreviews Notes
WB
1/1000 - 1/5000. Predicted molecular weight: 75 kDa.
IP
1/10 - 1/100.
Notes
WB
1/1000 - 1/5000. Predicted molecular weight: 75 kDa.
IP
1/10 - 1/100.
  • Application notes
    Is unsuitable for ICC or IHC-P.

    • Target

    • Function

      Catalyzes the deimination of arginine residues of proteins.

    • Tissue specificity

      Hair follicles, and epidermis at very low levels.

    • Sequence similarities

      Belongs to the protein arginine deiminase family.

    • Cellular localization

      Cytoplasm.
    • Information by UniProt

    • Database links

      • Alternative names

        • PADI3 antibody
        • PADI3_HUMAN antibody
        • PDI3 antibody
        • Peptidyl arginine deiminase, type III antibody
        • Peptidylarginine deiminase III antibody
        • Protein arginine deiminase type 3 antibody
        • Protein arginine deiminase type III antibody
        • Protein-arginine deiminase type III antibody
        • Protein-arginine deiminase type-3 antibody
        see all

      Images

      • Western blot - Anti-PADI3 / PAD3 antibody [EPR12165(B)] (ab172959)
        Western blot - Anti-PADI3 / PAD3 antibody [EPR12165(B)] (ab172959)
        All lanes : Anti-PADI3 / PAD3 antibody [EPR12165(B)] (ab172959) at 1/1000 dilution

        Lane 1 : Human fetal muscle lysate
        Lane 2 : Human skeletal muscle lysate
        Lane 3 : Human skin lysate

        Lysates/proteins at 10 µg per lane.

        Predicted band size: 75 kDa

      • Immunoprecipitation - Anti-PADI3 / PAD3 antibody [EPR12165(B)] (ab172959)
        Immunoprecipitation - Anti-PADI3 / PAD3 antibody [EPR12165(B)] (ab172959)

        Western blot analysis on immunoprecipitation pellet from Human fetal muscle lysate immunoprecipitated using ab172959 at 1/10 dilution.

      • Anti-PADI3 / PAD3 antibody [EPR12165(B)] (ab172959)
        Anti-PADI3 / PAD3 antibody [EPR12165(B)] (ab172959)

      References (3)

      Publishing research using ab172959? Please let us know so that we can cite the reference in this datasheet.

      ab172959 has been referenced in 3 publications.

      • Chang X  et al. PADI3 induces cell cycle arrest via the Sirt2/AKT/p21 pathway and acts as a tumor suppressor gene in colon cancer. Cancer Biol Med 16:729-742 (2019). PubMed: 31908891
      • Chai Z  et al. PADI3 plays an antitumor role via the Hsp90/CKS1 pathway in colon cancer. Cancer Cell Int 19:277 (2019). PubMed: 31708688
      • Ü Basmanav FB  et al. Mutations in Three Genes Encoding Proteins Involved in Hair Shaft Formation Cause Uncombable Hair Syndrome. Am J Hum Genet 99:1292-1304 (2016). PubMed: 27866708

      Customer reviews and Q&As

      Show All Reviews Q&A
      Submit a review Submit a question

      There are currently no Customer reviews or Questions for ab172959.
      Please use the links above to contact us or submit feedback about this product.

      Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
      For licensing inquiries, please contact partnerships@abcam.com